-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MOv18 IgE in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MOv18 IgE in Ovarian Cancer Drug Details: MOv18 IgEÂ is under development for the treatment of...
-
Product Insights
New![]()
Net Present Value Model: Celltrion Inc’s Omalizumab biosimilar
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Celltrion Inc's Omalizumab biosimilar Drug Details: Omalizumab biosimilar (CT-P39) is under development for the treatment of allergic asthma and chronic urticaria, chronic spontaneous urticaria,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PMB-104 in Allergic Asthma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PMB-104 in Allergic AsthmaDrug Details:PMB-104 is under development for the treatment of allergic asthma. The therapeutic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ociperlimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ociperlimab in Small-Cell Lung Cancer Drug Details: Ociperlimab (BGB-A1217) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ociperlimab in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ociperlimab in Non-Small Cell Lung Cancer Drug Details: Ociperlimab (BGB-A1217) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ociperlimab in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ociperlimab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: Ociperlimab (BGB-A1217) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ociperlimab in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ociperlimab in Solid Tumor Drug Details: Ociperlimab (BGB-A1217) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ociperlimab in Esophageal Squamous Cell Carcinoma (ESCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ociperlimab in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details: Ociperlimab (BGB-A1217) is under development for...
-
Product Insights
![]()
IG – Effingerstrasse Women’s Clinic Renovation – Bern
Equip yourself with the essential tools needed to make informed and profitable decisions with our IG - Effingerstrasse Women's Clinic Renovation - Bern report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AK-127 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AK-127 in Solid Tumor Drug Details: AK-127 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dargistotug in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Dargistotug in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)Drug Details:dargistotug (M-6223) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Omalizumab Biosimilar in Allergic Asthma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab biosimilar in Allergic Asthma Drug Details: Omalizumab biosimilar (BP-11) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXT-007 in Hemophilia A (Factor VIII Deficiency)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NXT-007 in Hemophilia A (Factor VIII Deficiency) Drug Details:NXT-007 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Omalizumab Biosimilar in Nasal Polyps (Nasal Polyposis)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab biosimilar in Nasal Polyps (Nasal Polyposis) Drug Details: Omalizumab biosimilar (BP-11) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – M-6223 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. M-6223 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: M-6223 is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Omalizumab Biosimilar in Chronic Urticaria Or Hives
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Omalizumab Biosimilar in Chronic Urticaria Or Hives Drug Details:Omalizumab biosimilar (CT-P39) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BAT-6021 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BAT-6021 in Solid Tumor Drug Details: BAT-6021 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dargistotug in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dargistotug in Solid Tumor Drug Details: dargistotug (M-6223) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119Â is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Omalizumab Biosimilar in Chronic Urticaria Or Hives
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab Biosimilar in Chronic Urticaria Or Hives Drug Details: Omalizumab biosimilar (BP-11) is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.